Norditropin Flexpro (Somatropin)

Somatropin binds to growth hormone receptors on cell surfaces, triggering the JAK2‑STAT5 signaling cascade. This leads to increased production of insulin‑like growth factor‑1 (IGF‑1) and other anabolic mediators that stimulate bone growth, protein synthesis, and metabolic effects on muscle and fat tissue.

The dose is individualized and set by the prescribing clinician based on factors such as age, weight, severity of deficiency, IGF‑1 levels, and clinical response. Patients should follow the prescriber’s instructions and attend regular monitoring visits.

Safety of somatropin during pregnancy and lactation has not been established. It should only be used if the potential benefits justify the potential risks to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Norditropin Flexpro is a recombinant somatropin formulation similar to other branded GH products such as Genotropin or Humatrope. All contain the same amino‑acid sequence, but differences may exist in device design, stability profile, and approved dosing regimens. Clinical efficacy is comparable when administered according to prescribing information.

The product must be stored refrigerated at 2‑8 °C, protected from light, and should not be frozen or shaken. Once reconstituted, it remains stable for a limited period (usually up to 28 days) when kept in the refrigerator, as indicated on the label.

Norditropin Flexpro is given by subcutaneous injection, typically into the thigh, abdomen, or upper arm. The injection device may be a pre‑filled pen or a vial requiring reconstitution. Patients should be trained by a healthcare professional on proper injection technique and site rotation.

Serious adverse events include intracranial hypertension, new‑onset diabetes or worsening glucose intolerance, and severe allergic reactions such as anaphylaxis. Patients should be monitored for persistent headaches, visual changes, rapid weight gain, or signs of hypersensitivity and report them promptly.

Norditropin Flexpro is contraindicated in individuals with active malignancy, known hypersensitivity to somatropin or any excipients, and in patients with acute critical illness following trauma or major surgery. Caution is also advised for those with uncontrolled diabetes or severe obesity.